United Therapeutics Corporation (NASDAQ:UTHR) recently announced that its new drug application (NDA) for oral treprostinil was accepted for review by the US Food and Drug Administration (FDA). The company is looking to get oral treprostinil approved for the treatment of pulmonary arterial hypertension (PAH). The FDA is scheduled to respond on the NDA for oral treprostinil by October 27, 2012.
United Therapeutics had applied for US approval of oral treprostinil in late December 2011. Remodulin … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards